GMO Institutional Investment Research

GMO’s research emphasizes a strategic shift away from traditional 60/40 portfolios, which are increasingly vulnerable to market shocks and valuation extremes, in favor of liquid alternatives that capture uncorrelated returns. The firm highlights the structural limitations of private equity, criticizing its reliance on return smoothing while advocating for strategies like Alternative Risk Premia to enhance capital efficiency. Concurrently, GMO identifies Japan as a high-conviction opportunity driven by the maturation of corporate reforms initiated under Abenomics, which have significantly bolstered profit margins and return on equity. Despite recent broad-market rallies, the firm argues that deep-value small-cap equities remain uniquely positioned for growth due to an undervalued yen and shifting global allocations. Ultimately, GMO’s outlook favors an active, engagement-oriented investment philosophy to navigate market inefficiencies across both domestic and international asset classes.